The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

While teclistamab looks on course to be the first BCMA-targeting bispecific antibody to reach the market, Pfizer is hot on J&J's heels with its BCMAxCD3 drug elranatamab and reported phase 2 data ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Conclusion: This study introduces a systematic framework that integrates LLMs with human expertise for gene prioritization. Our analysis identified CD38, TNFRSF17, and IGJ as the top candidates within ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

Blenrep (belantamab mafodotin) becomes the first BCMA-targeted drug for myeloma to be approved in the EU, and according to its label can be used to treat the blood cancer in adult patients who ...

However, some MM cells lose BCMA expression and cannot be targeted by the CAR T-cells. When the MYC gene is amplified, MM cells grow and divide rapidly making it resistant to therapy. Therefore ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...